Skip to main content

Table 3 Most common on-treatment AEs (≥ 3% incidence in any treatment group) (ITT population)

From: Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial

 

Placebo (n = 101)

FF dose

  

200 mcg OD/AM

(n = 105)

200 mcg OD/PM

(n = 103)

400 mcg OD/AM (n = 111)

400 mcg OD/PM

(n = 113)

200 mcg

BD

(n = 113)

Any AE, n (%)

28 (28)

36 (34)

32 (31)

43 (39)

35 (31)

38 (34)

   Headache

6 (6)

8 (8)

7 (7)

10 (9)

7 (6)

9 (8)

   Nasopharyngitis

4 (4)

8 (8)

8 (8)

3 (3)

7 (6)

6 (5)

   Bronchitis

2 (2)

1 (< 1)

3 (3)

4 (4)

4 (4)

0

   Pharyngolaryngeal pain

1 (< 1)

2 (2)

3 (3)

2 (2)

1 (< 1)

3 (3)

   Upper respiratory tract infection

2 (2)

3 (3)

2 (2)

2 (2)

1 (< 1)

1 (< 1)

   Dysphonia

0

1 (< 1)

1 (< 1)

1 (< 1)

2 (2)

3 (3)

   Rhinitis

0

4 (4)

1 (< 1)

0

1 (< 1)

2 (2)

   Rhinitis allergic

1 (< 1)

2 (2)

3 (3)

0

0

1 (< 1)

   Dizziness

0

3 (3)

0

2 (2)

1 (< 1)

0

   Influenza

2 (2)

0

1 (< 1)

3 (3)

0

0

   Pharyngitis

4 (4)

2 (2)

0

0

0

0

   Respiratory tract infection

0

1 (< 1)

0

3 (3)

1 (< 1)

0

  1. AE = adverse event; AM = morning dosing; BD = twice daily; OD = once daily; PM = evening dosing